EFFICACY AND SAFETY OF TMC435 IN COMBINATION WITH PEGINTERFERON α-2A AND RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 HCV PATIENTS: 24-WEEK INTERIM RESULTS FROM THE PILLAR STUDY

被引：0
|
作者：
Fried, Michael W. [1 ]
Buti, Maria [2 ]
Dore, Gregory J. [3 ]
Ferenci, Peter [4 ]
Jacobson, Ira [5 ]
Marcellin, Patrick [6 ]
Zeuzem, Stefan [7 ]
Lenz, Oliver [8 ]
Peeters, Monika [8 ]
Sekar, Vanitha J. [9 ]
De Smedt, Goedele [8 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Hosp Vall Hebron & Ciberehd, Barcelona, Spain
[3] St Vincents Hosp, Sydney, NSW 2010, Australia
[4] Allgemeines Krankenhaus Stadt Wien, Vienna, Austria
[5] Weill Cornell Med Coll, New York, NY USA
[6] Hop Beaujon, Clichy, France
[7] Klinikum Johann Wolfgang Goethe Univ, Med Klin 1, Frankfurt, Germany
[8] Tibotec BVBA, Beerse, Belgium
[9] Tibotec Inc, Titusville, NJ USA
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LB-5
引用
收藏
页码：403A / 404A
页数：2
相关论文
共 50 条
  • [1] Safety and tolerability of TMC435 in combination with peginterferon α-2a and ribavirin for treatment of HCV genotype 1 infection in treatment-naive and -experienced patients (PILLAR and ASPIRE trials)
    Fried, Michael W.
    Poordad, Fred
    Zeuzem, Stefan
    Ferenci, Peter
    Lenz, Oliver
    Ouwerkerk-Mahadevan, Sivi
    Peeters, Monika
    Sinha, Rekha
    Beumont, Maria
    HEPATOLOGY, 2012, 56 : 563A - 563A
  • [2] TMC435 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 PATIENTS: FINAL ANALYSIS OF THE PILLAR PHASE IIB STUDY
    Fried, Michael
    Buti, Maria
    Dore, Gregory J.
    Flisiak, Robert
    Ferenci, Peter
    Jacobson, Ira M.
    Marcellin, Patrick
    Manns, Michael P.
    Nikitin, Igor
    Poordad, F. Fred
    Sherman, Morris
    Zeuzem, Stefan
    Lenz, Oliver
    Peeters, Monika
    Sekar, Vanitha
    De Smedt, Goedele
    HEPATOLOGY, 2011, 54 : 1429A - 1429A
  • [3] TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY
    Lenz, Oliver
    Fevery, Bart
    Vijgen, Leen
    Verbeeck, Jannick
    Peeters, Monika
    Beumont, Maria
    Fried, Michael W.
    Picchio, Gaston
    HEPATOLOGY, 2011, 54 : 985A - 985A
  • [4] IMPACT OF IL28B GENOTYPE AND PRETREATMENT SERUM IP-10 IN TREATMENT-NAIVE GENOTYPE-1 HCV PATIENTS TREATED WITH TMC435 IN COMBINATION WITH PEGINTERFERONα-2A AND RIBAVIRIN IN PILLAR STUDY
    Aerssens, J.
    Fanning, G.
    Scholliers, A.
    Lenz, O.
    Peeters, M.
    De Smedt, G.
    Fried, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S5 - S6
  • [5] Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-2, a Phase III Trial
    Poordad, Fred
    Manns, Michael P.
    Marcellin, Patrick
    de Araujo, Evaldo Stanislau Affonso
    Buti, Maria
    Horsmans, Yves
    Janczewska, Ewa
    Villamil, Federico
    Peeters, Monika
    Lenz, Oliver
    Ouwerkerk-Mahadevan, Sivi
    Kalmeijer, Ronald
    Beumont-Mauviel, Maria
    GASTROENTEROLOGY, 2013, 144 (05) : S151 - S151
  • [6] SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL
    Manns, M.
    Marcellin, P.
    Poordad, F. P. Fred
    Stanislau Affonso de Araujo, E.
    Buti, M.
    Horsmans, Y.
    Janczewska, E. J. Ewa
    Villamil, F.
    Peeters, M.
    Lenz, O.
    Ouwerkerk-Mahadevan, S.
    Kalmeijer, R.
    Beumont-Mauviel, M.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S568 - S568
  • [7] SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
    Jacobson, I.
    Dore, G. J.
    Foster, G. R.
    Fried, M. W.
    Radu, M.
    Rafalskiy, V. V.
    Moroz, L.
    Craxi, A.
    Peeters, M.
    Lenz, O.
    Ouwerkerk-Mahadevan, S.
    Kalmeijer, R.
    Beumont-Mauviel, M.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S574 - S574
  • [8] OPERA-1 TRIAL: INTERIM ANALYSIS OF SAFETY AND ANTIVIRAL ACTIVITY OF TMC435 IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS
    Manns, M.
    Reesink, H.
    Moreno, C.
    Berg, T.
    Benhamou, Y.
    Horsmans, Y.
    Dusheiko, G.
    Flisiak, R.
    Meyvisch, P.
    Lenz, O.
    Sekar, V.
    van't Klooster, G.
    Simmen, K.
    Verloes, R.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S7 - S7
  • [9] TREATMENT OUTCOME AND RESISTANCE ANALYSIS IN HCV GENOTYPE 1 PATIENTS PREVIOUSLY EXPOSED TO TMC435 MONOTHERAPY AND RE-TREATED WITH TMC435 IN COMBINATION WITH PEGIFNα-2A/RIBAVIRIN
    Lenz, O.
    de Bruijne, J.
    Vijgen, L.
    Verbinnen, T.
    Weegink, C. J.
    van Marck, H.
    Vandenbroucke, I.
    Peeters, M.
    de Smedt, G.
    Simmen, K.
    Fanning, G.
    Picchio, G.
    Reesink, H. W.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S482 - S483
  • [10] 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS
    Chojkier, M.
    Everson, G.
    Muir, A.
    Bacon, B.
    Rodriguez-Torres, M.
    Bennett, M.
    Fried, M.
    Gordon, S.
    Gross, J.
    Nelson, D.
    Balart, L.
    Jonas, M.
    Szabo, G.
    Bloomer, J.
    McCullough, A.
    Nyberg, L.
    Smith, C.
    Bohm, O.
    Fox, A. W.
    Castelloe, E.
    Huyghe, M.
    Mento, S.
    Spada, A.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S165 - S165
12345